4.48
1.54%
-0.07
Bioventus Inc stock is currently priced at $4.48, with a 24-hour trading volume of 129.71K.
It has seen a -1.54% decreased in the last 24 hours and a -17.04% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.60 pivot point. If it approaches the $4.44 support level, significant changes may occur.
Bioventus Inc Stock (BVS) Financials Data
Bioventus Inc (BVS) Revenue 2024
BVS reported a revenue (TTM) of $512.35 million for the quarter ending December 31, 2023, a +0.04% rise year-over-year.
Bioventus Inc (BVS) Net Income 2024
BVS net income (TTM) was -$156.23 million for the quarter ending December 31, 2023, a +1.56% increase year-over-year.
Bioventus Inc (BVS) Cash Flow 2024
BVS recorded a free cash flow (TTM) of $7.98 million for the quarter ending December 31, 2023, a +131.86% increase year-over-year.
Bioventus Inc (BVS) Earnings per Share 2024
BVS earnings per share (TTM) was -$2.51 for the quarter ending December 31, 2023, a +2.71% growth year-over-year.
Bioventus Inc Stock (BVS) Latest News
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
Benzinga
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Bioventus Reports Upbeat Earnings, Joins Ranpak, Beachbody And Other Big Stocks Moving Higher On Tuesday
Benzinga
PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
GlobeNewswire Inc.
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
GlobeNewswire Inc.
About Bioventus Inc
Bioventus Inc. focuses on operating as a holding company for Bioventus LLC that operates as a medical device company. It develops and commercializes clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is based in Durham, North Carolina.
Cap:
|
Volume (24h):